Industry
Cell to Cure ApS
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
Failure Rate
66.7%
2 terminated/withdrawn out of 3 trials
Success Rate
33.3%
-53.2% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT06840275Phase 2Withdrawn
ASCs in Recently Diagnosed Non-ischemic Heart Failure
Role: lead
NCT05595681Phase 1Terminated
Effect of Mesenchymal Stem Cells on Healing of Foot Ulcers in Diabetes Patients.
Role: lead
NCT05602116Phase 1Completed
ASC - Autism Study
Role: lead
All 3 trials loaded